Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553824 · ClinicalTrials.gov registry record · Phase 1
FDA Approved Medication to Reduce Binge Eating and/or Purging
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02553824: Completed Phase 1 study, sponsored by Stanford University.
NCT02553824 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02553824, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will demonstrate the efficacy of Qsymia versus placebo in treating bulimia nervosa and binge eating disorder.
Interventions
- DRUG Placebo
- DRUG Phentermine/Topiramate-First
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-10-30 |
| Est. Completion | 2017-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553824
The ClinicalTrials.gov registry entry for NCT02553824 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02553824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02553824 about?
NCT02553824 is a clinical study titled "FDA Approved Medication to Reduce Binge Eating and/or Purging". This study will demonstrate the efficacy of Qsymia versus placebo in treating bulimia nervosa and binge eating disorder.
What is the current status of trial NCT02553824?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2015-10-30. Estimated completion is 2017-04-15.
What interventions are being tested in trial NCT02553824?
The interventions under investigation include: Placebo (DRUG), Phentermine/Topiramate-First (DRUG).
Who is sponsoring clinical trial NCT02553824?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.